Regeneron Pharmaceuticals (NASDAQ:REGN) Earns “Outperform” Rating from Royal Bank of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “outperform” rating reiterated by equities research analysts at Royal Bank of Canada in a note issued to investors on Monday, Benzinga reports. They presently have a $1,229.00 price objective on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target would indicate a potential upside of 14.73% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. TD Cowen lifted their price target on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Evercore ISI initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price objective for the company. Bank of America lifted their price objective on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. UBS Group lifted their price objective on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,008.96.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $1,071.19 on Monday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The business has a fifty day simple moving average of $974.69 and a two-hundred day simple moving average of $947.43. Regeneron Pharmaceuticals has a 1 year low of $684.80 and a 1 year high of $1,081.17. The company has a market capitalization of $118.03 billion, a P/E ratio of 31.65, a P/E/G ratio of 2.18 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). The company had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. On average, analysts expect that Regeneron Pharmaceuticals will post 37.12 earnings per share for the current year.

Insider Activity

In other news, CEO Leonard S. Schleifer sold 25,000 shares of the stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the sale, the chief executive officer now owns 408,200 shares of the company’s stock, valued at $399,729,850. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CEO Leonard S. Schleifer sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the transaction, the chief executive officer now owns 408,200 shares in the company, valued at $399,729,850. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Leonard S. Schleifer sold 22,830 shares of the company’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $979.23, for a total value of $22,355,820.90. Following the transaction, the chief executive officer now owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 61,971 shares of company stock valued at $61,217,654. 7.48% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Keynote Financial Services LLC bought a new position in Regeneron Pharmaceuticals in the first quarter worth $481,000. Hamilton Wealth LLC increased its holdings in shares of Regeneron Pharmaceuticals by 72.0% during the first quarter. Hamilton Wealth LLC now owns 461 shares of the biopharmaceutical company’s stock valued at $444,000 after acquiring an additional 193 shares in the last quarter. Railway Pension Investments Ltd increased its holdings in shares of Regeneron Pharmaceuticals by 1.4% during the first quarter. Railway Pension Investments Ltd now owns 28,100 shares of the biopharmaceutical company’s stock valued at $27,046,000 after acquiring an additional 400 shares in the last quarter. Cetera Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 114.1% during the first quarter. Cetera Advisors LLC now owns 5,218 shares of the biopharmaceutical company’s stock valued at $5,022,000 after acquiring an additional 2,781 shares in the last quarter. Finally, Cetera Investment Advisers increased its holdings in shares of Regeneron Pharmaceuticals by 156.8% during the first quarter. Cetera Investment Advisers now owns 9,753 shares of the biopharmaceutical company’s stock valued at $9,387,000 after acquiring an additional 5,955 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.